Skip to main content

Qualified laboratory research use only. Not for human or veterinary use, consumption, administration, compounding, diagnosis, or treatment.

RESEARCH USE ONLY
Tirzepatide Vespera catalog photography

Research material profile

Tirzepatide

Acylated dual GIP/GLP-1 receptor agonist peptide

Tirzepatide is an acylated peptide that activates the GIP and GLP-1 receptors. It is also the active ingredient in FDA-approved prescription products, but that fact does not make a separate research material an approved drug or a substitute for one.

Identity shorthand
39-amino-acid acylated peptide
Evidence map
Extensive drug literature; strict material boundary
Public page scope
Identity and literature context; no purchase offer
Commerce accessQualified laboratory buyers only

Pricing, availability, ordering, cart, and checkout remain inside the reviewed qualified-access portal.

Qualified catalog access

Plain-language identity

What Tirzepatide is

Tirzepatide is an acylated peptide that activates the GIP and GLP-1 receptors. It is also the active ingredient in FDA-approved prescription products, but that fact does not make a separate research material an approved drug or a substitute for one.

Research class
Acylated dual GIP/GLP-1 receptor agonist peptide
Sequence / identity shorthand
39-amino-acid acylated peptide
Evidence map
Extensive drug literature; strict material boundary
Identity boundary

Finished FDA-approved medicines and a Vespera research material differ in manufacturing, formulation, controls, labeling, regulatory status, and intended use. Evidence for an approved finished drug cannot validate a separate catalog material.

What researchers examine

  • Comparative GIP- and GLP-1-receptor pharmacology and signaling bias.
  • Peptide engineering, albumin binding, and analytical differentiation from related agonists.
  • How to separate published drug evidence from material identity and lot documentation.

How to read the evidence

  • The 2018 discovery paper characterized LY3298176 across receptor assays, animal models, and an early clinical proof-of-concept study.
  • Current FDA labeling identifies tirzepatide as a GIP- and GLP-1-receptor agonist in specific approved finished medicines.
  • Neither source establishes the composition, quality, safety, effectiveness, or intended use of this Vespera catalog material.

What this evidence does not establish

  • Do not transfer an approved product’s indications, dosing, administration, safety, or efficacy claims to a research material.
  • Vespera does not offer a prescription medicine, compounded drug, generic, or substitute for an approved tirzepatide product.
  • The live catalog title is preserved as production data; the scientific profile uses the accurate dual GIP/GLP-1 classification.

Documentation checklist

  • Match the exact catalog name, SKU, selected strength, lot, and analytical record.
  • Review identity, mass, purity, quantity, and other method-specific results as separate questions.
  • Keep all approved-drug labeling and clinical literature outside the procurement decision for a non-clinical research material.

Primary and official sources

Links are provided for source review. A citation is not an endorsement of nonresearch use.

  1. Coskun et al. — LY3298176 discovery and receptor characterization (2018)Primary discovery and proof-of-concept paper.
  2. FDA — current Zepbound prescribing informationOfficial labeling for an approved finished drug; not Vespera product documentation.
  3. FDA — proposal concerning tirzepatide on the 503B bulks list (2026)Current compounding-policy context.
Research use only. This profile contains identity and literature context only. It provides no dosing, administration, reconstitution, diagnosis, treatment, or personal-use guidance.